Scibase Q2’23: Germany is showing strength with the US breakthrough to come - Redeye

Redeye saw a Q2 report that was slightly weaker on the top line, with higher costs, making for a lower outcome than expected. The German market continues to develop well while we await a real breakthrough in the US, as the reimbursement process has been slow. We believe it is more of a timing issue than a real one. We have adjusted our estimates and left our fair value range unchanged but lowered our Base case slightly as we still see excellent growth opportunities going forward.

Länk till analysen i sin helhet: https://www.redeye.se/research/935356/scibase-q223-awaiting-the-breakthrough-for-reimbursement-in-us?utm_source=finwire&utm_medium=RSS